BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Distributors of construction materials and related equipment faced selling pressure on Monday after a report showed that U.S.